BNT162b2 (Pfizer)

BIOLOGICAL2 trials

Sponsors

Federal University of Espirito Santo, AstraZeneca

Conditions

COVID-19

Phase 3

Efficacy, Immunogenicity and Safety of Inactivated Vaccine (Coronavac) Against SARS-COV2 in Children and Adolescents

Federal University of Espirito SantoCOVID-19

Start: 2022-01-21End: 2023-03-21Target: 1120Updated: 2022-02-04

Unknown Phase

Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study

CompletedNCT05697705

AstraZenecaCOVID-19

Start: 2022-07-22End: 2023-05-18Updated: 2024-11-21

Related Papers

Second booster doses of adenoviral- and mRNA-based COVID-19 vaccines increase protection against COVID-19 hospitalization: Final analysis from the REFORCO-Brazil real-world effectiveness study during Omicron.

2025-03-10

Immune Response to an Inactivated Vaccine of SARS-CoV-2 (CoronaVac) in an Indigenous Brazilian Population: A Cohort Study

Vaccines2024-04-102 citations

IMUNOGENICIDADE E SEGURANÇA DA VACINA INATIVADA (CORONAVAC) COMPARADA À VACINA BNT162B2 (PFIZER) CONTRA SARS-COV-2 EM CRIANÇAS E ADOLESCENTES (PROJETO CURUMIM)

The Brazilian Journal of Infectious Diseases2023-10-01

NÃO INFERIORIDADE DA RESPOSTA IMUNE EM CRIANÇAS DE 3 E 4 ANOS APÓS A VACINA INATIVADA (CORONAVAC) COMPARADO A CRIANÇAS MAIORES E ADULTOS

The Brazilian Journal of Infectious Diseases2023-10-01

COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and Omicron.

2023-09-127 citations